The latent HIV-1 reservoir that resides in resting CD4+ (rCD4+) T cells of infected individuals on combination antiretroviral therapy (cART) is a major obstacle to a cure. A primary challenge in defining this reservoir is the lack of a high-throughput, sensitive and robust assay that can quantify the size of the inducible replication-competent pool of latent HIV-1. Currently, the quantitative viral outgrowth assay (Q-VOA) that is widely used is labor intensive, time consuming and expensive, and is not amenable to a high-throughput format. Here we report on the development of a TZM-bl cell based assay (TZA) for the quantification of replication-competent latent HIV-1, which is fast, sensitive, robust and amenable to a high-throughput format.
The strategy for quantifying inducible replication competent HIV-1 in rCD4+T cells by TZA involves two steps: (i) induction of latent HIV-1 from rCD4+T cells by anti-CD3/CD28 antibodies; and (ii) quantification of induced replication competent HIV-1 in the TZM-bl cell based assay . Using TZA, Q-VOA and a simultaneous ultrasensitive subpopulation staining/hybridization in situ (SUSHI) assay we quantified the size of the inducible replication-competent pool of latent HIV-1 in rCD4+ T cells isolated from 13 aviremic HIV-1 infected individuals on suppressive cART from the Pittsburgh Multicenter AIDS Cohort Study.
For the TZA, the amount of replication competent HIV-1 was found to range 1.2-141 (mean 46.4) infectious units per million (IUPM). By contrast, the IUPM values for the Q-VOA ranged 0.28-2.37 (mean 0.70), which is almost 70-fold lower (p=0.0029). To confirm the high levels of IUPM obtained from the TZA assay we applied the SUSHI assay in parallel to anti-CD3/CD28 activated rCD4+ T cells from 10 out of 13 donors. The number of HIV-1 RNA positive cells per million rCD4+T cells in the SUSHI assay was similar in magnitude to the TZA assay ranging from 10 to 240 (mean 75). In subsets of HIV-infected subjects, we also evaluated fractional HIV-1 provirus expression (fPVE). For 9 subjects the fPVE as measured by the TZA ranged from 0.12-13.93% (mean 4.03%), while fPVE as measured by the Q-VOA ranged from 0.02- 0.9% (mean 0.14%).
Using the novel TZA assay, we show that the size of the inducible latent HIV-1 reservoir in virally suppressed individuals on cART is significantly larger than previous estimates using the Q-VOA, which could pose a challenge for the irradication of latent virus in rCD4+ T cells in these patients.